Business Description
Rapport Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US75383L1026
Total Employee Number:
84Description
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 44.13 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.09 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 45.94 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -20.46 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 67.57 | |||||
9-Day RSI | 63.54 | |||||
14-Day RSI | 60.91 | |||||
3-1 Month Momentum % | 3.04 | |||||
6-1 Month Momentum % | 21.58 | |||||
12-1 Month Momentum % | 128.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 27.08 | |||||
Quick Ratio | 27.08 | |||||
Cash Ratio | 26.64 | |||||
Days Sales Outstanding | 1.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.5 | |||||
Shareholder Yield % | -0.41 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -611.03 | |||||
Net Margin % | -536.39 | |||||
EBITDA Margin % | -606.03 | |||||
FCF Margin % | -403.54 | |||||
OCF Margin % | -401.49 | |||||
ROE % | -26.59 | |||||
ROA % | -25.15 | |||||
ROIC % | -618.06 | |||||
ROC (Joel Greenblatt) % | -963.48 | |||||
ROCE % | -29.66 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 98.68 | |||||
PB Ratio | 4.23 | |||||
Price-to-Tangible-Book | 4.24 | |||||
EV-to-EBIT | -12.53 | |||||
EV-to-EBITDA | -12.63 | |||||
EV-to-Revenue | 76.54 | |||||
EV-to-Forward-Revenue | 77.14 | |||||
EV-to-FCF | -18.97 | |||||
| Price-to-Net-Current-Asset-Value | 4.36 | |||||
| Price-to-Net-Cash | 4.43 | |||||
Earnings Yield (Greenblatt) % | -7.98 | |||||
FCF Yield % | -4.04 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RAPP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rapport Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 20 | ||
| EPS (TTM) ($) | -2.6 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 71.18 | ||
| 14-Day RSI | 60.91 | ||
| 14-Day ATR ($) | 2.676564 | ||
| 20-Day SMA ($) | 39.2575 | ||
| 12-1 Month Momentum % | 128.93 | ||
| 52-Week Range ($) | 13.43 - 43.76 | ||
| Shares Outstanding (Mil) | 47.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rapport Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rapport Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 118 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 27 days | ||
| General meeting for 2026 | 2026-06-10 13:00 | 35.84 (-3.94%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 13:20 | 36.10 (-2.85%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 08:45 | 34.90 (-3.91%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 37.06 (+3.87%) | ||
| Guidance call for 2026 | 2026-03-17 09:30 | 27.62 (-1.11%) | ||
| Leerink Global Healthcare Conference | 2026-03-11 09:20 | 29.63 (+1.47%) | ||
| The Citizens Life Sciences Conference | 2026-03-10 14:15 | 30.54 (+0.63%) | ||
| Annual report for 2025 | 2026-03-10 | 30.54 (+0.63%) |
Show
Entries
Rapport Therapeutics Inc Frequently Asked Questions
What is Rapport Therapeutics Inc(RAPP)'s stock price today?
The current price of RAPP is $41.79. The 52 week high of RAPP is $43.76 and 52 week low is $13.43.
When is next earnings date of Rapport Therapeutics Inc(RAPP)?
The next earnings date of Rapport Therapeutics Inc(RAPP) is 2026-08-07 Est..
Does Rapport Therapeutics Inc(RAPP) pay dividends? If so, how much?
Rapport Therapeutics Inc(RAPP) does not pay dividend.
Guru Commentaries on NAS:RAPP
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Rapport Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers